Eledon Pharmaceuticals (ELDN) risk factors, FY2025 10-K

Risks Related to Our Operations

1. 01Our short operating history and shifts in our business strategy may make it difficult to evaluate the success of our business to date and to assess our future viability23% rewritten
2. 02We have incurred significant operating losses since our inception and expect that we will continue to incur losses over the next several years and may never achieve or maintain profitability
3. 03operate as a public company
4. 04We will require additional funding to be able to complete the development of our lead drug candidate. If we are unable to raise capital, we will be forced to significantly alter our business strategy, substantially curtail our current operations, or liquidate and cease operations altogether
5. 05the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims75% rewritten
6. 06successfully commercialize one or more of our product candidates, additional financing may not be available to us on acceptable terms, or at allNew
7. 07Our product candidates are in the early stages of clinical development and may not be successfully developed. If we are unable to successfully develop and commercialize these or any other product candidate, or if we experience significant delays in doing so, our business will be materially harmed
8. 08Public health crises, including pandemics or epidemics could adversely affect our business
9. 09delays or disturbances in enrollment and trial execution, for example, because clinical trial sites may be unable to operate normally, or patients may elect to forego visits to medical facilities or undertake voluntary medical procedures
10. 10Unfavorable global economic conditions could adversely affect our business, financial condition and results of operations
11. 11Adverse conditions in the financial markets, including bank failures, could adversely affect our liquidity and financial performance
12. 12have the product removed from the market after obtaining marketing approval
13. 13If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented and expenses for the development of our product candidates could increase
14. 14unacceptable risk-benefit profile or unforeseen safety issues or adverse effects
15. 15Our ability to conduct clinical trials in some jurisdictions outside of the United States may be adversely affected
16. 16changes in country or regional regulatory requirements
17. 17If severe adverse events or unacceptable side effects are identified during the development of our product candidates, we may need to abandon or limit our development of some of our product candidates
18. 18Our future success depends on our ability to retain executives and key employees and to attract, retain and motivate qualified personnel in the future

Risks Related to Regulatory Approval of Our Product Candidates and Other Compliance Matters

1. 19If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, or the approvals may be for a narrow indication, we may not be able to commercialize our product candidates, and our ability to generate revenue may be materially impaired
2. 20If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired
3. 21injunctions or the imposition of civil or criminal penalties
4. 22Legislation regulating the pharmaceutical and healthcare industries may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain49% rewritten
5. 23The compromise of privacy, security, integrity or confidentiality of sensitive information related to our business or failure to comply with confidentiality and data privacy obligations could have a material adverse effect on our business
6. 24European data collection is governed by restrictive regulations governing the collection, use, processing and cross-border transfer of personal information
7. 25If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business

Risks Related to the Commercialization of Our Product Candidates

1. 26Even if any of our product candidates receives marketing approval, we may fail to achieve the degree of market acceptance by physicians, patients, third-party payers and others in the medical community necessary for commercial success
2. 27If our current product candidates, or a future product candidate receives marketing approval and we, or others, later discover that the product is less effective than previously believed or causes undesirable side effects that were not previously identified, the ability to market the product could be compromised
3. 28Any of these events could have a material and adverse effect on our operations and business. The commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired
4. 29We face substantial competition, which may result in others discovering, developing or commercializing competing products before or more successfully than we do
5. 30Generic products are currently available, with additional generic products expected to become available over the coming years, potentially creating pricing pressure. If our product candidates achieve marketing approval, we expect that they will be priced at a significant premium over competitive generic products
6. 31The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue
7. 32Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop

Risks Related to Our Dependence on Third Parties

1. 33the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us
2. 34We depend on CROs and other contracted third parties to perform non-clinical and clinical testing and certain other research and development activities. As a result, the outcomes of the activities performed by these organizations will be, to a certain extent, beyond our control

Risks Related to Our Intellectual Property

1. 35in the United States and internationally that are related to our novel technologies and product candidates. This patent portfolio includes issued patents and pending patent applications covering pharmaceutical compositions and methods of useNew
2. 36We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful
3. 37We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms
4. 38If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
5. 39We may be subject to claims of misappropriation of trade secrets from former employers of Company personnel

Risks Related to Our Common Stock

1. 40We expect our stock price to be volatile, and the market price of our common stock may drop unexpectedly
2. 41Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stock39% rewritten
3. 42Provisions in our corporate charter documents and under Delaware law could make an acquisition of the Company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management
4. 43We do not expect to pay any cash dividends in the foreseeable future